Nexgenix Pharmaceuticals (United States)

Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2

Jaishri O. Blakeley, D. Gareth Evans, John R. Adler et al. · American Journal of Medical Genetics Part A · 2011 · 136 citations

Medicine, Neurology, Oncology +17

In vitro studies of steroid hormones in neurofibromatosis 1 tumors and schwann cells

Lauren Fishbein, Xuelian Zhang, Lori B. Fisher et al. · Molecular Carcinogenesis · 2007 · 46 citations

Medicine, Oncology, Pathology +17

Therapeutic Potential of HSP90 Inhibition for Neurofibromatosis Type 2

Karo Tanaka, Ascia Eskin, Fabrice Chareyre et al. · Clinical Cancer Research · 2013 · 43 citations · Full text

Medicine, Oncology, Pharmacology +16

Inhibition of HSP90 with Pochoximes: SAR and Structure‐Based Insights

Sofía Barluenga, Jean‐Gonzague Fontaine, Cuihua Wang et al. · ChemBioChem · 2009 · 42 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +11

A novel small molecule HSP90 inhibitor, NXD30001, differentially induces heat shock proteins in nervous tissue in culture and in vivo

Jieun Cha, Kyle J.H. St. Louis, Miranda L. Tradewell et al. · Cell Stress and Chaperones · 2013 · 27 citations · Full text

Life Sciences, Neurology, Neuroscience +17